How to cite: Hussain, Maha H. “PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations” December, 2019. Accessed Nov 2025. https://grandroundsinurology.com/profound-trial-shows-increased-rpfs-in-mcrpc-patients-with-brca1-brca2-and-atm-mutations/
PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations – Summary:
Maha H. Hussain, MD, FACP, FASCO, and Celestia S. Higano, MD, discuss the PROfound Trial, which demonstrated increased radiographic progression-free survival (rPFS) with the use of olaparib for mCRPC patients displaying the genetic mutations BRCA1, BRCA2, and ATM. Dr. Hussain outlines previous research of genetic mutations in mCRPC that led to this study, the study design and rationale of using two cohorts with specific mutations (BRCA1, BRCA2, and ATM) and non-specific mutations (other genetic alterations), and results that demonstrate promise for gene-targeted therapies in the future.
ABOUT THE AUTHOR
Maha H. Hussain, MD, FACP, FASCO is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology of the Department of Medicine, and Deputy Director of the GU Oncology Program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine in Chicago. In this role, Hussain plays a critical role in establishing the overall strategic direction, policy and priorities of the Lurie Cancer Center.. She is also a practicing oncologist and clinical researcher.